Navigation Links
Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc
Date:11/6/2014

Baltimore, MD, November 6, 2014 - Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused on research in aging and age related diseases announced a research collaboration with the international leader in personalized medicine of cancer, Champions Oncology, Inc (OTC: CSBR).

"There are many companies utilizing advances in genomics for personalized medicine, but Champions Oncology's TumorGraft technology is unique in a way that it can validate the chemotherapy regimen experimentally generating vast amounts of valuable data. Our bioinformatic analysis showed that molecular signatures of patient tumor grafts in mice are very similar to signatures of cancer in patients before and after treatment. We established this research collaboration to further validate these preliminary findings", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.

Champions TumorGrafts are a personalized approach used to guide physician treatment decisions for cancer patients. A piece of the patient's living tumor is removed during surgery or biopsy and engrafted in immune-deficient mice. After the TumorGraft grows, still closely resembling the patient's tumor, Champions Oncology tests drug treatments in the TumorGraft and measures the response. TumorGraft has demonstrated high rates of predictability using multiple therapies, including single-agent and combination, chemotherapy regimens and targeted biological drugs.

Every TumorGraft is preserved as a living sample for future patient use. These banked TumorGrafts can be re-grown and tested in the event of cancer progression or recurrence. In oncology drug development, TumorGraft models are utilized extensively by pharmaceutical and biotechnology organizations to predict the clinical effectiveness of their compounds in targeted patient populations.

"Our preliminary collaboration with Insilico Medicine showed some exciting results that may be of interest to both the academic and industry communities", said KerenPaz, chief Scientific Officer at Champions Oncology.

In the scope of this research collaboration Insilico Medicine will analyze a portion of Champions Oncology gene expression data sets from tumor grafts before and aftertreatment with chemotherapy drugs and compare the signaling pathway activation state (SPAS) changes with the SPAS changes in human patients.

"Champions' Tumorgraft technology stems from many years of breakthrough science generated in the most credible, productive and innovative cancer research laboratories headed by Dr. David Sidransky, who's work we greatly admire. We believe that the TumorGraft technology has broad applications in drug discovery and drug repurposing in aging and age-related diseases that were previously overlooked. This research collaboration may pave the way for a comprehensive drug discovery and development pipeline, where drugs and drug candidates may be selected and prioritized using in silico approaches and tested in human tissues engrafted into Champions Oncology mice or other animal models", said Qingsong Zhu, PhD, Chief Operating Officer, Insilico Medicine, Inc.


'/>"/>

Contact: Michael Petr
michael.petr@insilicomedicine.com
InSilico Medicine, Inc.
@InSilicoMeds
Source:Eurekalert

Related biology news :

1. InSilico Medicine CEO to present at Oxford University
2. Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago
3. Timing is everything in new nanotechnology for medicine, security and research
4. Cancer research implies future for personalized medicine, reduction in animal testing
5. Medicine, energy topics of Kavli lectures at American Chemical Society meeting
6. After the Genome tackles tough questions about medicine, miracles and morality
7. Young malaria parasites refuse to take their medicine, may explain emerging drug resistance
8. Personalized health care will revolutionize 21st century medicine, says NJIT professor
9. University of Maryland School of Medicine, NIH study pinpoints brain areas role in learning
10. HITLAB Announces Inaugural HITLAB Innovators Summit
11. Elsevier announces launch of open journal: Biomolecular Detection and Quantification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2018)... ... , ... Illumina, Kaiser Permanente, ResMed and Aetna were just a few of ... cooking events company has hosted an impressive guest list of Fortune 500 businesses, namely ... group who visits receives a completely customized experience, right down to the menu and ...
(Date:12/13/2018)... ... December 13, 2018 , ... Biocompare, the ... entitled “What Researchers Need to Know about Antibody Manufacturing” . This educational ... series. The goal of this film is to educate scientists about antibody production, ...
(Date:12/10/2018)... ... December 10, 2018 , ... ... to advance their shared goal of accelerating the development of the Regenerative Medicine ... systems to TRT’s core technology around human umbilical cord perivascular cells (HUCPVCs). ...
Breaking Biology News(10 mins):
(Date:12/13/2018)... ... December 13, 2018 , ... Microbial Discovery Group ... This has been part of their strategic plan and an important milestone in ... custom fermentation opportunities for MDG within the $44 Billion human probiotic market. This ...
(Date:12/5/2018)... ... ... STRmix™ – sophisticated forensic software capable of resolving mixed DNA profiles previously thought to ... of third-degree sexual assault, a felony punishable by imprisonment for up to 15 years. ... cushions on which the sexual assault was alleged to have taken place. , Jennifer ...
(Date:11/27/2018)... , ... November 27, 2018 , ... New patients in ... Dr. Dan Myers’ practice for treatment, with or without a referral. Dr. Myers has ... tools, including porcelain veneers, dental implants, bridges and custom crowns. , As a ...
(Date:11/20/2018)... ... ... Each year Forbes receives thousands of nominations for candidates wishing to be selected for ... years of age. The Forbes 30 Under 30 list showcases the top 30 individuals ... Science. , In 2017, Visikol CEO Dr. Michael Johnson was named to the ...
Breaking Biology Technology: